BCL2 and non-Hodgkin lymphoma: The functioning mechanism of rituximab involves killing CD20+ B lymphocytes by antibody-dependent and complement-mediated cytotoxicity, inducing apoptosis of B-lymphocyte-associated malignant tumor cells, enhancing the sensitivity of drug-resistant cell lines to chemotherapeutic drugs, and downregulating bcl-2 gene expression.[11] Analytical research reveals that chemotherapy combined with rituximab can increase the CR rate of NHL, reduce the possibility of failure and relapse, and prolong disease-free and overall survival.